The Estée Lauder Companies Shares New Preclinical and Clinical Findings at World Congress of Dermatology Spanning Emerging Research Areas that Support Skin Health and Longevity
Retrieved on:
Thursday, July 6, 2023
Histology, La mer, Senior, Skin care, Xeroderma, SIRT2, 3D, Elastin, Clinical trial, Enzyme, EL, Ageing, Glycation, SIRT, AGE, Woman, Hyaluronic acid, Research, Sirtuin, Science, Thought, DE, Clinique, Congress, Parity, Beauty, Erythema, UV, ELC, Randomized controlled trial, Irritation, Hyperpigmentation, BrainScope Company, Inc., Advanced glycation end-product, Ozone, Knowledge, Poster, R, Longevity, Autostereogram, Human, NYSE, Identity matrix, Skin, N-Acetylglucosamine, Cosmetics, Medical imaging, Dietary supplement, Medical device, Dermatology
NEW YORK, July 6, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and several of its brands presented a range of novel preclinical and clinical findings at the 25th World Congress of Dermatology, held this week in Singapore. The poster and satellite symposium presentations reflect a strong portfolio of prestige beauty and skin care brands effectively translating biological learnings and progressive research efforts into meaningful innovation, including better methods to care for and protect skin.
Key Points:
- With rapidly emerging knowledge and advancements from the dermatologic and scientific communities, the science of skin care has never been more important," said Lisa Napolione, Senior Vice President, Global Research & Development (R&D).
- "As we live longer, research on health span and longevity will only accelerate.
- To meet these innovation challenges, we are thinking differently, and in a manner enabled by novel science across all our global laboratories and clinics."
- Using 3D skin models, researchers studied the anti-glycation properties of 6 compounds to determine their capacities to reduce auto-fluorescence in 3D skin models.